Back to Search
Start Over
Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report
- Source :
- Italian Journal of Pediatrics, Vol 47, Iss 1, Pp 1-9 (2021), Italian journal of pediatrics, 47(1):149, 1-9. BMC, Italian Journal of Pediatrics
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Background Besides major clinical/biochemical features, neutropenia and inflammatory bowel disease (IBD) constitute common complications of Glycogen storage disease type Ib (GSD Ib). However, their management is still challenging. Although previous reports have shown benefit of empagliflozin administration on neutropenia, no follow-up data on bowel (macro/microscopic) morphology are available. We herein present for the first time longitudinal assessment of bowel morphology in a GSD Ib child suffering from Crohn disease-like enterocolitis treated with empagliflozin. Case presentation A 14-year-old boy with GSD Ib and severe IBD was (off-label) treated with empagliflozin (20 mg/day) after informed oral and written consent was obtained from the patient’s parents. No adverse events were noted. Clinical symptoms and stool frequency improved within the first week of treatment. Pediatric Crohn disease activity index (PCDAI) normalised within the first month of treatment. Abdomen magnetic resonance imaging (MRI) performed 3 months after treatment initiation showed dramatic decrease in disease activity and length. Similar findings were reported on histology at 5.5 months. At 7.5 months hemoglobin levels normalised and fecal calprotectin almost normalised. Improved neutrophil count, metabolic control and quality of life were also noted. G-CSF dose was decreased by 33% and the patient was partly weaned from tube feeding. Conclusions This is the first report presenting extensive gastrointestinal morphology follow-up in a GSD Ib patient receiving empagliflozin. The present case suggests that empagliflozin can be safe and effective in inducing IBD remission in GSD Ib patients and can even postpone surgery. Future studies are required to confirm its effect over time and assess its benefit in various disease stages. The development of an international collaborating networks for systematic data collection is worthy.
- Subjects :
- Male
0301 basic medicine
AUTOIMMUNITY
Empagliflozin
Case Report
Glycogen Storage Disease Type I
GUIDELINES
Pediatrics
Gastroenterology
Inflammatory bowel disease
0302 clinical medicine
Crohn Disease
Glucosides
Granulocyte Colony-Stimulating Factor
Glycogen Storage Disease Type Ib
Continuous glucose monitoring
Enterocolitis
Remission Induction
NEUTROPHIL DYSFUNCTION
Absolute neutrophil count
medicine.symptom
COLITIS
medicine.medical_specialty
Neutropenia
Adolescent
5-anhydroglucitol
RJ1-570
03 medical and health sciences
Glycogen storage disease type Ib
Internal medicine
MANAGEMENT
medicine
Humans
Benzhydryl Compounds
Adverse effect
Sodium-Glucose Transporter 2 Inhibitors
1,5-anhydroglucitol
business.industry
medicine.disease
030104 developmental biology
Calprotectin
business
030217 neurology & neurosurgery
INFLAMMATORY-BOWEL-DISEASE
1B
Subjects
Details
- ISSN :
- 18247288 and 17208424
- Volume :
- 47
- Database :
- OpenAIRE
- Journal :
- Italian Journal of Pediatrics
- Accession number :
- edsair.doi.dedup.....b079e9435d3019f0277442f1ca33ba4e